Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal 1

2289 - Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)


08 Sep 2017


Gastrointestinal tumours, non-colorectal 1


Cytotoxic Therapy;  Oesophageal Cancer;  Gastric Cancer;  Prostate Cancer


Josep Tabernero


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


J. Tabernero1, P.M. Hoff2, L. Shen3, A. Ohtsu4, M.A. Shah5, K. Cheng6, C. Song6, H. Wu7, J. Eng-Wong6, Y. Kang8

Author affiliations

  • 1 Vall D'hebron University Hospital And Institute Of Oncology (vhio), Universitat Autonoma de Barcelona, 08035 - Barcelona/ES
  • 2 Centro De Oncologia, Hospital Sirio Libanes, 01308-050 - Sao Paulo/BR
  • 3 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN
  • 4 Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital, Kashiwa/JP
  • 5 Meyer Cancer Center At Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, 10065 - New York/US
  • 6 Product Development Oncology, Genentech, Inc, 94080 - South San Francisco/US
  • 7 Biostatistics, Biometrics, Roche (China) Holding Ltd, 201203 - Shanghai/CN
  • 8 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2289


Targeting HER2 with H + CT significantly improves overall survival (OS) vs CT alone in patients (pts) with HER2-positive mGC/GEJC. In HER2-positive metastatic breast cancer, P + H + docetaxel significantly improves progression-free survival (PFS) and OS vs placebo (PLA) + H + docetaxel. We therefore assessed the efficacy and safety of adding P to H + CT in pts with HER2-positive mGC/GEJC.


JACOB (NCT01774786) is a double-blind, randomised, PLA-controlled, Phase III study in mGC/GEJC. Pts were randomised 1:1 to PLA + H + CT (standard cisplatin/fluoropyrimidine regimen) or P + H + CT. P and H were given every 3 weeks until disease progression or unacceptable toxicity (P at 840 mg, H: 8 mg/kg loading and 6 mg/kg maintenance doses). CT was given as per standard regimens/doses. Stratification factors were world region, prior gastrectomy and HER2 immunohistochemistry score. Primary endpoint was OS. Secondary endpoints included PFS and safety. JACOB was estimated to have 80% power to detect a significant improvement in OS (hazard ratio [HR] 0.777) at the final efficacy analysis after 502 events (overall two-sided α-level 5%).


From 10 Jun 2013 to 12 Jan 2016, 388 pts were randomised to P + H + CT and 392 to PLA + H + CT. After a median OS follow-up of approx. 2 years, 504 patients had died, 242 in the P + H + CT arm (median OS 17.5 months) and 262 in the PLA + H + CT arm (median OS 14.2 months) (HR 0.84, 95% confidence interval [CI] 0.71–1.00; p = 0.0565). Median PFS was 8.5 months and 7.0 months respectively (HR 0.73, 95% CI 0.62–0.86). The safety profile was generally comparable between treatment arms except for diarrhoea (all grades: 61.6% in P + H + CT vs 35.1% in PLA + H + CT). Incidence of symptomatic and asymptomatic left ventricular systolic dysfunction was low and similar in both arms.


The study failed to demonstrate a statistically significant improvement in OS with the addition of P to H + CT, although a 3.3-month increase in median OS was observed. P was generally well tolerated and no new safety signals were identified. Further analyses will be presented.

Clinical trial identification

Protocol number: BO25114; ClinicalTrials.gov NCT01774786

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd


F. Hoffmann-La Roche Ltd.


J. Tabernero: Advisory board: Amgen, Bayer, Boehringer-Ingelheim, Celgene, Chugai, Genentech, Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Symphogen, Taiho, and Takeda. P.M. Hoff: Corporate-sponsored research: Roche. L. Shen: Advisory board: Hengrui, Merck, Roche, BMS. Corporate-sponsored research: Taiho, Hengrui, Merck, Roche AZ. A. Ohtsu: Corporate-sponsored research: BMS. M.A. Shah: Advisory board: Lilly, Inc. Corporate-sponsored research to institution: Roche, Boston Biomedical, Gilead. K. Cheng: Stock ownership: Genentech. Employee of Genentech. C. Song: Stock ownership: Roche. Corporate-sponsored research: Roche. Employee of Roche. H. Wu: Employee of Roche (China) Holding Ltd. J. Eng-Wong: Employee of Genentech. Y-K. Kang: Advisory board: Roche, Novartis, Ono, Daehwa, LSK Biopharma, Blueprint, Taiho, BMS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.